prikaz prve stranice dokumenta Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?
  Preuzmi
PDF 1.03 MB
Znanstveni rad - Izvorni znanstveni rad
Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?
Farmaceutski glasnik, 77 (2021), 3-4; 125-134. urn:nbn:hr:163:754620
Antolić, Andrea; Maleš, Željan; Galović, Petra; Tomičić, Maja; Bojić, Mirza

Institucijski repozitorij: Repozitorij Farmaceutsko-biokemijskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Antolić, A., Maleš, Ž., Galović, P., Tomičić, M. i Bojić, M. (2021). Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?. Farmaceutski glasnik, 77. (3-4), 125-134. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:163:754620

Antolić, Andrea, et al. "Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?." Farmaceutski glasnik, vol. 77, br. 3-4, 2021, str. 125-134. https://urn.nsk.hr/urn:nbn:hr:163:754620

Antolić, Andrea, Željan Maleš, Petra Galović, Maja Tomičić i Mirza Bojić. "Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?." Farmaceutski glasnik 77, br. 3-4 (2021): 125-134. https://urn.nsk.hr/urn:nbn:hr:163:754620

Antolić, A., et al. (2021) 'Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?', Farmaceutski glasnik, 77(3-4), str. 125-134. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:163:754620 (Datum pristupa: 09.11.2024.)

Antolić A, Maleš Ž, Galović P, Tomičić M, Bojić M. Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?. Farmaceutski glasnik [Internet]. 2021. [pristupljeno 09.11.2024.];77(3-4):125-134. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:754620

A. Antolić, Ž. Maleš, P. Galović, M. Tomičić i M. Bojić, "Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?", Farmaceutski glasnik, vol. 77, br. 3-4, str. 125-134, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:754620. [Citirano: 09.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:163:754620
Podaci o radu
Naslov (hrvatski)Mogu li biljni pripravci propolisa i ginkga smanjiti hiperreaktivnost trombocita u bolesti COVID-19?
AutorAndrea Antolić
AutorŽeljan Maleš
AutorPetra Galović
AutorMaja Tomičić
AutorMirza Bojić
Autorova ustanovaSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
(Zavod za farmaceutsku botaniku)
Autorova ustanovaSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
(Zavod za farmaceutsku kemiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Farmacija
Farmacija
Sažetak (engleski)
Propolis is flavonoid rich source that has shown numerous beneficial biological effects such as antibacterial, antiviral, antitumoral, antiaggregatory, and hepatoprotective. Ginkgo has been used as a dietary supplement for enhancement of cognitive functions. The aim of this study was assessment of the effect of propolis and ginkgo extracts on primary hemostasis and verify whether the use of a combination of propolis and ginkgo extracts in the prevention of cardiovascular diseases is justified. Commercially available extracts were assessed by impedance aggregometry on the whole blood samples of healthy subjects collected at the Croatian Institute of Transfusion Medicine. Two aggregation inducers were used: ADP (adenosine diphosphate, weak agonist of platelet aggregation) and TRAP (hexapeptide surrogate of thrombin, strong inducer of platelet aggregation). In an ADP induced aggregation assay, propolis showed an antiaggregatory effect at a concentration of 10 μM. In the same test, the antiplatelet effect of ginkgo extract was absent. In the hexapeptide-induced thrombin mimetic (TRAP) aggregation test, propolis showed an antiplatelet effect at a concentration of 20 μM as well as ginkgo extract. Combinations of propolis and ginkgo in a ratio of 1:25 and 1:50 showed an antiplatelet effect at 20 μM concentrations of extracts. Combination of propolis and ginkgo is justified from a pharmacodynamic aspect, as propolis and ginkgo have different mechanisms of action because they act on different signaling pathways of aggregation.
Ključne riječi (hrvatski)
Jezikhrvatski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - domaća recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFarmaceutski glasnik
Brojčani podacivol. 77, br. 3-4, str. 125-134
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:754620
Datum objave publikacije2021
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2021-04-26 09:38:03